Design considerations for a multicenter randomized controlled trial of early surgery for mesial temporal lobe epilepsy

Department of Neurology, UCLA, Los Angeles, California 90095-1769, USA.
Epilepsia (Impact Factor: 4.57). 10/2010; 51(10):1978-86. DOI: 10.1111/j.1528-1167.2010.02641.x
Source: PubMed


To describe the trial design for the multicenter Early Randomized Surgical Epilepsy Trial (ERSET). Patients with pharmacoresistant epilepsy are generally referred for surgical treatment an average of two decades after onset of seizures, often too late to avoid irreversible disability. ERSET was designed to assess the safety and efficacy of early surgical intervention compared to continued pharmacotherapy.
ERSET is a randomized controlled, parallel group clinical trial with blinded outcome adjudication. Participants are patients with mesial temporal lobe epilepsy (MTLE) older than the age of 12 who have had pharmacoresistant seizures for not >2 years and are determined by detailed evaluation to be surgical candidates prior to randomization. The primary outcome measure is seizure freedom in the second year of a 2-year follow-up period. Health-related quality of life (HRQOL), neurocognitive function, ancillary outcomes, and adverse events were also measured.
Significant methodologic problems addressed by the study design included the following: recruitment of participants early in the course of epilepsy; establishment of operational definitions for "pharmacoresistant" and "early"; and standardization of diagnostic testing, medical treatment, and surgical interventions across multiple centers.
Rigorous trial designs to assess surgical interventions in epilepsy are necessary to provide evidence to guide treatment. This article is the first of a series; trial results will be reported in subsequent publications.

Download full-text


Available from: John Langfitt, Jun 02, 2014
16 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: The accurate prediction of individual outcomes after epilepsy surgery represents a key challenge facing clinicians. It requires a precise understanding of surgical candidacy and the optimal timing of surgery to maximize a range of outcomes, including medical, psychosocial, cognitive, and psychiatric outcomes. We promote careful consideration of how epilepsy has affected an individual's developmental trajectory as key to constructing more differentiated profiles of postsurgical risk or resilience across multiple outcome measures. This life span approach conceives surgery as a crucial "turning point" in an individual's development from which varied outcome trajectories may follow. This helps clinicians understand the expectations patients and families bring to surgery, and emphasizes the interplay of factors that determine a patient's outcome. It also promotes comprehensive, longitudinal assessment of outcome using data analytical techniques that capture individual differences and identify subgroups with similar trajectories. An ongoing challenge facing clinicians is the development of an outcome classification system that incorporates outcomes other than seizures. We illustrate two emerging areas of research shaping how we define surgical candidacy and predict outcome: (1) using cortico-cortical evoked potentials to identify pathways of seizure propagation and cortico-cortical networks mediating cortical functions, and (2) predicting postoperative depression using a model that incorporates psychosocial and neurobiological factors. The latter research points to the importance of routine follow-up and postoperative psychosocial rehabilitation, particularly in patients deemed at "high risk" for poor outcomes so that early treatment interventions can be implemented. Significantly more research is needed to characterize those patients with poor outcomes who may require re-surgery.
    Epilepsy & Behavior 04/2011; 22(1):23-31. DOI:10.1016/j.yebeh.2011.02.011 · 2.26 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The mainstay of epilepsy surgery is the resection of a presumed seizure focus or disruption of seizure propagation pathways. These approaches cannot be applied to all patients with medically refractory epilepsy (MRE). Since 1997, vagus nerve stimulation has been a palliative adjunct to the care of MRE patients. Deep brain stimulation (DBS) in select locations has been reported to reduce seizure frequency in small studies over the past three decades. Recently published results from the SANTE (Stimulation of the Anterior Nuclei of Thalamus for Epilepsy) trial-the first large-scale, randomized, double-blind trial of bilateral anterior thalamus DBS for MRE-demonstrate a significant reduction in seizure frequency with programmed stimulation. Another surgical alternative is the RNS™ System (NeuroPace, Mountain View, CA), which uses a closed-loop system termed responsive neurostimulation to both detect apparent seizure onsets and deliver stimulation. Recently presented results from the RNS™ pivotal trial demonstrate a sustained reduction in seizure frequency with stimulation, although comprehensive trial results are pending.
    Current Neurology and Neuroscience Reports 05/2011; 11(4):404-8. DOI:10.1007/s11910-011-0209-8 · 3.06 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Using the most recent evidence, we provide an update on epilepsy surgery, focusing on its effectiveness, reasons for underutilization, considerations of candidacy and timing for referral for epilepsy surgery evaluation. The course of illness of epilepsy is being characterized. Well conducted studies describe the patterns of seizure remission and relapse with medical therapy and also in response to epilepsy surgery. Epilepsy surgery is highly effective in selected patients with drug-resistant epilepsy (DRE). The risk-benefit of epilepsy surgery is well known and consistent around the world. However, epilepsy surgery remains underutilized. A randomized controlled trial and Clinical Practice Guidelines (CPGs) supporting epilepsy surgery have had no discernible impact on referral rates for epilepsy surgery evaluation. Criteria and guidelines are being developed for identifying patients who need to be referred for epilepsy surgery evaluation. Quality indicators for epilepsy care now also include the need to consider surgical candidacy every 3 years in DRE. New developments in imaging and neurophysiology promise to help clinicians identify and treat patients more accurately. Surgery is effective but underused. Comprehensive interventions to translate evidence to practice in epilepsy surgery are urgently needed.
    Current opinion in neurology 04/2012; 25(2):187-93. DOI:10.1097/WCO.0b013e328350baa6 · 5.31 Impact Factor
Show more